WELCOME to this Patient Advocacy organization's informational archive provided by MS Views and News
· Our live MS educational seminars average 72 people per educational program. SINCE our first program in February 2010, we have hosted more than 150 educational programs.
· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews
* Be Empowered with beneficial Multiple Sclerosis (MS) information - See our listings of upcoming Educational Programs --
Visit MS Views and News.org
View all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.
Sunday, November 29, 2015
Saturday, November 28, 2015
Video recorded - November 2015
a 17minute:38second (17:38) video recorded interview on
MS Medications, MRI, MS Relapse and Vitamin D
Program date 11.14.15
Company's work in personalized immunotherapies honored for 3rd consecutive year
Friday, November 27, 2015
Friday, November 27, 2015, 12:00 Hrs [IST]
Takeda Pharmaceutical Company Limited, a research-based global company, announced that the multiple sclerosis treatment drug, 'Copaxone subcutaneous injection 20 mg syringe' (glatiramer acetate) has become available in Japan.
This drug has been developed by Teva Pharmaceutical Industries Ltd. as a subcutaneous injection administered once daily, to prevent the relapse of multiple sclerosis. Copaxone was designated as an orphan drug by the Japanese Ministry of Health, Labour and Welfare (MHLW) in March 2009, and a request was received from the MHLW in May 2010 for its development as an "unapproved drug highly needed in medical care". In March 2013, Takeda and Teva entered into a licensing agreement for commercialisation of this drug in Japan, and on September 28, 2015 Takeda obtained NDA approval. It was listed in the NHI (National Health Insurance) Price List today.
Multiple sclerosis is assumed to be an autoimmune disease, the hallmark sign of which is inflammatory demyelination of the central nervous system characterized by demyelinating plaques in the brain and the spinal cord. Common symptoms of multiple sclerosis include visual problems, ocular motor abnormality, paresthesia, muscle weakness, spasticity, urinary dysfunction, and cognitive impairment. This disease may present as a primary progressive type, which takes a chronic progressive course from its early onset; a relapsing-remitting type, which repeats a pattern of relapse and remission; or a secondary progressive type that shifts to a progressive course later. More than 80 per cent of patients are categorized as having the relapsing-remitting type. Multiple sclerosis is estimated to affect approximately 18,000 individuals in Japan, with its prevalence tending to increase.
Monday, November 23, 2015
Lay out nothing directly towards supporting us.
This comes from your purchases with Amazon Smile
click the above banner to shop and support our mission
Sunday, November 22, 2015
The study also highlighted the good psychometric properties of the symbol digit modalities test (SDMT), Maria P. Amato, MD, of the University of Florence, Italy,
"It seems important to stress that, in optimal clinical conditions, where a neuropsychologist can take care of the cognitive assessment, it is preferable to
The study showed that when BICAMS was compared with other commonly used neuropsychological batteries used in MS, such as the Brief Repeatable Battery (BRB), neither BICAMS nor BRB were equivalent to SDMT in the assessment of CI in MS. This is in keeping with the recent literature, pointed out the investigators.
"On the basis of our results, the agreement between the BICAMS and the BRB is fair
CME event "RISKY BUSINESS": Understanding and Attenuating Risk Associated with Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis
In this neuroscience CME Live and On Demand faculty will share the evidence and their insights with health care providers to enable them to collaboratively engage patients in a discussion about their disease and develop shared treatment goals to improve outcomes in patients with MS.
Healthcare Providers: Click here to learn more of this event
Saturday, November 21, 2015
Dr. Walker's presentation begins at approximately 7 minutes into this video.
Mastering the prism of 7 VIBRANTs : mental, physical, emotional, spiritual, professional, financial, and social.